Daiichi Sankyo Condemns Falsely-represented Product - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Daiichi Sankyo Condemns Falsely-represented Product

Daiichi Sankyo warned that a product being sold online to consumers in Malaysia and Indonesia is illegally using Daiichi Sankyo’s name, logo, and registered trademark and is not manufactured or sold by any Daiichi Sankyo Group companies or subcontractors. The package of the falsely represented product, Glutax 4G Premium, is similar to one of Daiichi Sankyo’s Asian prescription-drug products, the company reported. Daiichi Sankyo placed advertisements in Malaysian and Indonesian consumer publications to warn consumers of the deceit.

Daiichi Sankyo said that the advertisements were published because protecting consumers is its highest priority. The advertisements were published in Malaysian newspapers at the end of January and in February magazine issues, as well as in Indonesian newspapers at the end of February and in March or April magazine issues. The company is preparing to take legal action and is consulting with Malaysian authorities, the company announced in a March 5, 2013 press release.


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans

Click here